BEDFORD, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the successful closing of the deal with Oxford Biomedica plc ...
OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the ...
Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & ...
New expedited service line designed for biotechs with timeline constraints, launched in response to client demand Can accelerate timeline to GMP manufacturing by up to nine months, driven by key ...
Live webcasts and recordings of presentations, where available, will be accessible under ‘Results, Reports, Presentations & Webcasts’ in the Investor Relations section of OXB’s website at www.oxb.com.
OXB (formerly Oxford BioMedica), a listed gene and cell therapy firm, is anticipating strong growth in its latest half-year trading update. The company expects to report revenues of between £70m and ...
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results